TC
BPMC

Torno Capital’s Blueprint Medicines BPMC Stock Holding History

Torno Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,800
Closed -$627K – 291
2023
Q4 		$627K Buy
+6,800
New +$441K 0.13% 110

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Torno Capital's BPMC Position: Q2 2024 in Review

Torno Capital sold out of Blueprint Medicines (BPMC) in Q2 2024, closing a stake of 2,000 shares — an estimated $190K sold.

Torno Capital first reported a position in BPMC in Q4 2023 and held it in 2 quarters. The position peaked at $2.12M in Q4 2023. 305 funds tracked by Wall St. Rank hold BPMC as of Q2 2024.

  • Torno Capital reported no remaining Blueprint Medicines position as of Q2 2024 after selling out during the quarter.
  • Torno Capital sold 2,000 Blueprint Medicines shares in Q2 2024, an estimated $190K.
  • Torno Capital first reported a position in Blueprint Medicines in Q4 2023 and held it in 2 quarters.
  • Torno Capital's Blueprint Medicines position peaked at $2.12M in Q4 2023.
  • 305 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2024.

Based on Torno Capital's 13F filing for Q2 2024, filed 14 Aug 2024.